IRA Medicare Inflation Penalties: Implications for Manufacturer Pricing and Contract Strategy Decision Making

Available On Demand

What do ‘pricing inflation penalties’ actually mean for manufacturers of biopharma products?

Explore the impact of the Inflation Reduction Act (IRA) on biopharmaceutical product net prices and contract strategies as manufacturers adapt to new U.S. market conditions.

In this webinar, Trinity Life Sciences’ Evidence, Value, Access & Pricing practice experts will provide a high-level review of IRA policy updates before exploring the implications for currently marketed Medicare Part B and Part D therapies, as well as for future product launches.

Don’t miss your chance to gain an in-depth understanding of the IRA’s ramifications on future product pricing, contracting and net revenues. Register for our webinar to explore representative case studies that demonstrate a number of price management actions that manufacturers can use to avoid the penalties, but also understand situations in which accepting penalty rebates could actually optimize brand net revenues.

Key Topics

1. Overview of key policy updates in the Inflation Reduction Act
2. Deep dive into the impact of the Inflation Reduction Act on pricing
3. Recommendations about the actions and strategies to explore in addressing inflation penalties

Complete the form below to watch the on-demand webinar.

We would contact you in accordance with our Privacy Policy, which we invite you to visit for details about our data privacy practices, including, where appropriate, how you may access and correct the personal data we store or withdraw consent to the collection, use or disclosure of such information. We will not share your email address or personal information. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.